TRU-SENTIMENT · DeltaNeutral
SYRE Trading Analysis - 10/14/2026 03:11 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
SYRE (Spyre Therapeutics Inc. Common Stock) at $79.08. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $0 vs put $9,980. RSI 40.5.
- Symbol
- SYRE
- Price
- $79.08
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- medium
- Published
- 2026-10-14 15:11:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From SYRE_options_20261014_1511.json (Delta 40-60 only):
Call Volume: $0.00 (0.0%) Put Volume: $9,980.00 (100.0%) Total: $9,980.00
- Sentiment: Bearish
- 0 call contracts / 11 put contracts; 0 call trades / 2 put trades.
- Pure directional conviction is entirely put-sided — bears dominate near-term expectations.
- Filter ratio 0.7% of total options analyzed (302) met delta criteria — thin but unambiguous flow.
- Divergence: technicals already bearish, sentiment confirms (no bullish divergence).
Key Statistics: SYRE
Fundamental Snapshot
Valuation
| P/E (trailing) | 1.70 |
| EPS (trailing 12 mo) | $-2.17 |
| Market cap | $7.39B |
| Shares outstanding | 93.5M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.99 |
| 52-week low | $18.71 |
| 52-week high | $110.17 |
| Historical volatility | 60.4% |
Ownership & trading
| Institutional ownership | 67.3% |
| Average daily volume | 1.6M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Recent general-knowledge context for SYRE (Syros Pharmaceuticals), a clinical-stage biotech focused on selective chromatin modulation for cancer and hematologic malignancies:
- SYRE has historically been tied to clinical trial readouts for its lead asset (e.g., tamibarotene in myelodysplastic syndromes); any delay or mixed data can trigger sharp moves.
- Biotech sector has faced funding-pressure headlines in 2026 as rates remained elevated, disproportionately impacting pre-revenue names like SYRE.
- October 2026 options activity suggests speculative hedging increased ahead of potential fall pipeline updates.
- No confirmed earnings date in provided data, but fiscal year end is listed as 2025-12-01, implying annual reporting cadence separate from daily trade flow.
- Context: The embedded data shows a sharp Oct 6 drop (close 80.46 from 92.08 open) on massive volume (3.54M), consistent with a binary catalyst or sector de-risk event rather than steady fundamental erosion.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for SYRE:
- Trailing EPS is -2.17; company is not profitable (negative earnings).
- Trailing P/E is 1.70, but with negative EPS this ratio is non-meaningful for valuation quality.
- PEG ratio, forward P/E, forward EPS, profit margins, ROE, debt/equity, and free cash flow are all null — not available in data.
- Revenue growth, total revenue, and gross/operating/net margins are null — no trends computable.
- Dividend yield 0.0; no dividend distributed.
- Market cap 7.39B; shares outstanding 93.45M; institutional ownership 67.31%.
- Beta 1.99 — high systemic risk relative to market.
- 52-week range: 18.71 low to 110.17 high; current price (~79–81) sits in lower-middle of range.
- Historical volatility 60.35%; average volume 1.62M vs recent daily volumes often exceeding 1M.
- Analyst consensus and target price are null — no street view in data.
Fundamentals show a pre-revenue, high-beta biotech with negative EPS. This diverges from the technical picture of a recent sharp drawdown and bearish options flow, as fundamentals alone do not explain the Oct 6 volume spike or current sub-SMA pricing.
Current Market Position
From minute bars (2026-10-13 to 2026-10-14 14:40):
- 2026-10-13 09:30 open 85.12, slid to 82.90 by 09:50, closed daily at 81.89 on 974,816 volume.
- 2026-10-14 last bar 14:40 close 79.08, down from 79.48 at 14:20; intraday low 79.08.
- Intraday momentum is downward: each late-session bar made lower closes (79.81 → 79.45 → 79.39 → 79.20 → 79.08).
- Daily history shows Oct 6 close 80.46 after 92.08 open (range low 79.36) on 3.54M volume — major bearish rupture.
Technical Analysis
Technical Indicators
- Price below SMA 5 (82.81), SMA 20 (87.48), and SMA 50 (93.85) — fully bearish alignment, no golden cross.
- RSI 40.47 = weak momentum, not yet oversold (<30).
- MACD -2.64 below signal -2.11, histogram -0.53 = bearish momentum persisting.
- Bollinger: price near lower band (79.15); lower band close to intraday 79.08 support.
- 30-day range: price at ~81.89 is 23% above 30D low (77.05) and 14% below 30D high (95.27).
True Sentiment Analysis (Delta 40-60 Options)
From SYRE_options_20261014_1511.json (Delta 40-60 only):
Call Volume: $0.00 (0.0%) Put Volume: $9,980.00 (100.0%) Total: $9,980.00
- Sentiment: Bearish
- 0 call contracts / 11 put contracts; 0 call trades / 2 put trades.
- Pure directional conviction is entirely put-sided — bears dominate near-term expectations.
- Filter ratio 0.7% of total options analyzed (302) met delta criteria — thin but unambiguous flow.
- Divergence: technicals already bearish, sentiment confirms (no bullish divergence).
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.